Article
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.
Blood - 1 Jul 2006
Hughes Timothy, Deininger Michael, Hochhaus Andreas, Branford Susan, Radich Jerald, Kaeda Jaspal, Baccarani Michele, Cortes Jorge, Cross Nicholas C P, Druker Brian J, Gabert Jean, Grimwade David, Hehlmann Rüdiger, Kamel-Reid Suzanne, Lipton Jeffrey H, Longtine Janina, Martinelli Giovanni, Saglio Giuseppe, Soverini Simona, Stock Wendy, Goldman John M
Abstract excerpt
The introduction in 1998 of imatinib mesylate (IM) revolutionized management of patients with chronic myeloid leukemia (CML) and the second generation of tyrosine kinase inhibitors may prove superior to IM. Real-time quantitative polymerase chain reaction (RQ-PCR) provides an accurate measure of the total leukemiacell mass and the degree to which BCR-ABL transcripts are reduced by therapy correlates with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.